2026-01-23 - Analysis Report
**Financial Report: Eli Lilly (LLY)**

**Company Overview:** Eli Lilly is a multinational pharmaceutical company developing and marketing human medicines.

**Return Rate Comparison:**

* Ticker: LLY
* Cumulative Return: 284.15%
* Comparison Stock (VOO): Cumulative Return 92.53%
* Divergence (simply the difference in cumulative return on the last day of the data): 191.62%
* Relative Divergence: 77.40% (indicating the current position when the minimum-maximum fluctuation range is set to 100)

**Alpha, Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|-----|-------|------|--------|
| 2016-2018 | 37.0% | 14.3% | 32.0% | 0.7 | 103.7B |
| 2017-2019 | 36.0% | 14.7% | 19.0% | 0.7 | 117.8B |
| 2018-2020 | 30.0% | 20.9% | 9.0% | 0.7 | 151.4B |
| 2019-2021 | 49.0% | 20.9% | 5.0% | 0.7 | 247.6B |
| 2020-2022 | 59.0% | 20.9% | 60.0% | 0.7 | 328.0B |
| 2021-2023 | 116.0% | 18.0% | 115.0% | 0.5 | 522.6B |
| 2022-2024 | 123.0% | 27.0% | 104.0% | 0.6 | 692.1B |
| 2023-2025 | 183.0% | 29.9% | 121.0% | 0.7 | 963.4B |

**Recent Stock Price Fluctuations:**

* Close: $1,087.38
* Last-Market: $1087.38
* Previous Close: $1078.52
* Change: +0.82
* 5-day SMA: $1,055.71
* 20-day SMA: $1,070.62
* 60-day SMA: $1,021.53

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence:**

* Market Risk Indicator (MRI): 0.90 (High Investment Recommended)
* RSI: 52.30
* PPO: -0.28
* Hybrid Signal: Buy (Cash 0%)
* Recent (20 days) relative divergence change: -3.10 (worsening)
* 7-day Rank change: 2 (+) (rank up)
* 7-day Dynamic Expected Return change: -1.20 (-) (worsening)
* Expected Return (%): 57.10%

**Recent News & Significant Events:**

* [2026-01-05] Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
* [2026-01-16] Buy The Dip In LLY Stock? - Forbes
* [2026-01-22] Eli Lilly stock price today: LLY edges up after FDA “breakthrough” tag as Feb. 4 earnings near - TechStock²
* [2026-01-06] Warning: This Skyrocketing Stock Has a Hidden Risk - The Motley Fool
* [2026-01-22] Eli Lilly and Company $LLY Shares Sold by Simplicity Wealth LLC - MarketBeat
* [2026-01-22] Study sheds light on weight regain after GLP-1 discontinuation - Seeking Alpha

**Analyst Opinions:**

Analyst Consensus:

* Key: Buy
* Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
* Opinions: 28
* Target Price (avg/high/low): 1110.71 / 1500.00 / 770.00

**Recent Earnings Analysis:**

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.3 | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2025-10-30 | 1.08 | 11.44 B$ |

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

**Comprehensive Analysis (Summary of previous items):**

Based on the provided data, Eli Lilly (LLY) has shown significant growth in cumulative return compared to the S&P 500 (VOO), with a divergence of 191.62%. The company's recent stock price fluctuations indicate a short-term bullish trend with a 5-day SMA at $1,055.71 and a 20-day SMA at $1,070.62. The RSI, PPO, and Delta_Previous_Relative_Divergence indicators suggest a cautious investment approach, while the Expected Return of 57.10% and Analyst Consensus of Buy indicate long-term investment potential.

The recent news and significant events suggest a mix of positive and negative sentiment, including a warning of a hidden risk. The quarterly earnings analysis indicates a steady increase in revenue and profit margin, while the capital and profitability data show a decline in ROE.

Overall, the comprehensive analysis suggests that Eli Lilly (LLY) is a promising investment opportunity, but with caution advised due to the short-term fluctuations and potential risks highlighted in the news and significant events.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.